Title | Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Goldman SL, Hassan C, Khunte M, Soldatenko A, Jong Y, Afshinnekoo E, Mason CE |
Journal | Front Genet |
Volume | 10 |
Pagination | 133 |
Date Published | 2019 |
ISSN | 1664-8021 |
Abstract | Leukemia, specifically acute myeloid leukemia (AML), is a common malignancy that can be differentiated into multiple subtypes based on leukemogenic history and etiology. Although genetic aberrations, particularly cytogenetic abnormalities and mutations in known oncogenes, play an integral role in AML development, epigenetic processes have been shown as a significant and sometimes independent dynamic in AML pathophysiology. Here, we summarize how tumors evolve and describe AML through an epigenetic lens, including discussions on recent discoveries that include prognostics from epialleles, changes in RNA function for hematopoietic stem cells and the epitranscriptome, and novel epigenetic treatment options. We further describe the limitations of treatment in the context of the high degree of heterogeneity that characterizes acute myeloid leukemia. |
DOI | 10.3389/fgene.2019.00133 |
Alternate Journal | Front Genet |
PubMed ID | 30881380 |
PubMed Central ID | PMC6405641 |
Grant List | R01 MH117406 / MH / NIMH NIH HHS / United States R01 AI125416 / AI / NIAID NIH HHS / United States R01 ES021006 / ES / NIEHS NIH HHS / United States R25 EB020393 / EB / NIBIB NIH HHS / United States R21 AI129851 / AI / NIAID NIH HHS / United States R01 NS076465 / NS / NINDS NIH HHS / United States |